menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    GLOBENEWSWIRE

    Anavex`s Alzheimer Treatment Result Published In Journal

    GLOBENEWSWIRE

    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    GLOBENEWSWIRE

    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    GLOBENEWSWIRE

    Anavex Life`s Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    GLOBENEWSWIRE

    NANOBIOTIX to Attend Investor Conferences in November

    GLOBENEWSWIRE

    Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    GLOBENEWSWIRE

    Anavex’s experimental drug fails Rett syndrome study, stock falls

    ENDPTS

    Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine

    GLOBENEWSWIRE

    Anavex Initiates Regulatory Submission of Blarcamesine for Alzheimers Disease

    GLOBENEWSWIRE

    Anavex`s Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy

    GLOBENEWSWIRE

    Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Completion of ANAVEX EXCELLENCE Phase 2/3 Trial

    GLOBENEWSWIRE

    ANAVEX Announces Issuance of Property Compositions Patent for ANAVEX2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX

    GLOBENEWSWIRE

    Anavex Announces Exceeding of Enrollment Target for the ANAVEX 2-73 EXCELLENCE Phase 2/3 Trial

    GLOBENEWSWIRE

    Anavex (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints

    GLOBENEWSWIRE

    Anavex Life Announces Late-Breaking Presentation of P 2b/3 Data of Oral ANAVEX®

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Provides Supplemental Information on ANAVEX 2-73 Phase 3 Trial

    GLOBENEWSWIRE

    After changing study goals, Anavex touts Rett syndrome win

    FIERCEBIOTECH

    Anavex Life Sciences Announces Positive Data for ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Reports New Publication in Medical Journal on Alzheimer`s Disease

    GLOBENEWSWIRE

    Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application

    GLOBENEWSWIRE

    Homology Medicines Announces Presentation of Positive Data from the Dose

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Positive Results Pha2 Trial ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex completes ANAVEX2-73 US phase 2 studies in Rett syndrome

    PHARMABIZ

    Anavex completes mid-stage study of lead drug in rare brain development disorder

    SEEKINGALPHA

    Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73

    PRESS RELEASE

    Anavex starts dosing patients in Rett syndrome trial

    WWW.CLINICALTRIALSARENA

    Anavex Life Sciences Announces 1st Patient in EXCELLENCE Ph 2/3 Trial

    GLOBENEWSWIRE

    Anavex surpasses 50% of enrollment target of the ANAVEX2-73 phase 2 trial

    PHARMABIZ

    Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX

    GLOBENEWSWIRE

    Anavex receives Health Canada & UK MHRA approvals to ph 2b/3 trial of ANAVEX2-73

    PHARMABIZ

    Anavex Life Sciences Receives Regulatory Approval from UK MHRA 2b/3 ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Initiation of First-in-Human Ph 1 of ANAVEX®3-71

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces FTD Granted by U.S. FDA for ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Announces Achievement of Enrollment Target the ANAVEX®2-73

    GLOBENEWSWIRE

    Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data

    BUSINESS WIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.